Cytek Biosciences, Inc.
CTKBHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The $610.9M market capitalization puts CTKB squarely in small-cap range for its industry. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Market Cap
$610.9M
Beta
1.19
P/E (TTM)
—
P/E (Fwd)
67.14
EPS (TTM)
$-0.63
EPS (Fwd)
$0.07
ROE
-23.0%
ROA
-6.3%
Cash
$262.0M
Total Debt
$26.5M
Free CF
$9.3M
52W Change
19.6%
Annual Financials
Cash vs Debt
Where CTKB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CTKB finished 6.59% above its 150-day moving average ($4.40) and 1.52% above its 200-day moving average ($4.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTKB overbought or oversold?
At the September 3, 2026 close, CTKB's RSI(14) was 43.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $262.0M in cash and $26.5M in debt, CTKB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $9.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -23.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $164.0M (2022) to $201.5M (2025), reflecting a 23% increase over the period.
With cash comfortably exceeding debt, CTKB has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cytek Biosciences, Inc.'s trajectory.